新型CD19-KIRS2/Dap12-BB CAR-T治疗复发难治B细胞肿瘤3例  

Novel CD19-KIRS2/Dap12-BB CAR-T Treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors

作　　者：计胜伟 华田 王娇娇 邵灵燕 陈子涵 刘佳颖 程海 陈伟 孙财 王雪 徐开林 曹江 JI Sheng-Wei;HUA Tian;WANG Jiao-Jiao;SHAO Ling-Yan;CHEN Zi-Han;LIU Jia-Ying;CHENG Hai;CHEN Wei;SUN Cai;WANG Xue;XU Kai-Lin;CAO Jiang(Department of Hematology,The Affiliated Hospital of Xuzhou Medical University,Xuzhou 221002,Jiangsu Province,China)

机构地区：[1]徐州医科大学附属医院血液科,江苏徐州221002

出　　处：《中国实验血液学杂志》2023年第6期1860-1865,共6页Journal of Experimental Hematology

基　　金：徐州市医学领军人才培养项目(XWRCHT20210028)。

摘　　要：目的:探讨新型CD19-KIRS2/Dap12-BB嵌合抗原受体T细胞(CAR-T)治疗复发/难治性B细胞肿瘤的安全性及有效性。方法:以2020年6至11月采用新型CD19-KIRS2/Dap12-BB CAR-T治疗的3例复发/难治性B细胞肿瘤患者为研究对象,包括急性B淋巴细胞白血病1例,非霍奇金淋巴瘤2例,观察疗效及不良反应。结果:急性B淋巴细胞白血病患者取得完全缓解和微小残留病灶转阴,2例非霍奇金淋巴瘤患者取得部分缓解。急性B淋巴细胞白血病患者发生2级细胞因子释放综合征,2例非霍奇金淋巴瘤患者发生1级细胞因子释放综合征,3例患者均发生Ⅱ-Ⅳ级血液学不良反应,上述不良反应均可控且可逆。3例患者无进展生存期分别为143、199、91 d,总生存期分别为282、430、338 d。结论:新型CD19-KIRS2/Dap12-BB CAR-T治疗3例复发/难治性B细胞肿瘤患者近期疗效显著,且不良反应可控,而远期疗效有待进一步提高。Objective:To investigate the safety and efficacy of novel CD19-KIRS2/Dap12-BB chimeric antigen receptor T cells(CAR-T cells) in the treatment of relapsed/refractory B-cell malignancy(R/R BCM).Methods:Three patients with R/R BCM treated with novel CD19-KIRS2/Dap12-BB CAR-T cells from June 2020 to November 2020 were enrolled,including 1 case of B-cell acute lymphoblastic leukaemia(B-ALL) and 2 cases of non-Hodgkin's lymphoma(NHL),and the efficacy and adverse reactions were observed.Results:After CAR-T cells infusion,patient with B-ALL achieved complete remission(CR) and minimal residual disease(MRD) turned negative,and 2 patients with NHL achieved partial remission(PR).Grade 2 cytokine release syndrome(CRS) occurred in B-ALL patient,grade 1 CRS occurred in 2 NHL patients,and grade II to IV hematologic adverse reactions occurred in 3 patients,all of which were controllable and reversible.The progression-free survival(PFS) of the 3 patients was 143,199,and 91 days,and overall survival(OS) was 282,430,and 338 days,respectively.Conclusion:The novel CD19-KIRS2/Dap12-BB CAR-T cells in treatment of 3 patients with R/R BCM have significant short-term efficacy and controllable adverse reactions,but the long-term efficacy needs to be further improved.

关 键 词：B细胞肿瘤 嵌合抗原受体T细胞 KIRS2/Dap12 

分 类 号：R733[医药卫生—肿瘤]